US Patent

US11266641 — Formulations of a somatostatin modulator

Method of Use · Assigned to Crinetics Pharmaceuticals Inc · Expires 2041-09-07 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects formulations of a somatostatin modulator and methods of using them in the treatment of conditions that benefit from somatostatin activity modulation.

USPTO Abstract

Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Drugs covered by this patent

paltusotine-hydrochloride (PALTUSOTINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4283`	—	paltusotine-hydrochloride
`U-4283`	—	paltusotine-hydrochloride

Patent Metadata

Patent number: US11266641
Jurisdiction: US
Classification: Method of Use
Expires: 2041-09-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Crinetics Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.